| atenolol vs bendroflumethiazide | No demonstrated result suggested myocardial infarction (fatal and non fatal) by 63% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 1.02 [0.80 1.29] | p=1.00 | 0 | 8700 | 1 | MRC I (vs diuretics), | | Cardiovascular death | 0.92 [0.65 1.29] | p=1.00 | 0 | 8700 | 1 | MRC I (vs diuretics), | | myocardial infarction (fatal and non fatal) | 1.63 [1.13 2.36] | p=0.04 | 0 | 2183 | 1 | MRC I (vs diuretics), | | stroke (fatal and non fatal) | 1.22 [0.82 1.82] | p=1.00 | 0 | 2183 | 1 | MRC I (vs diuretics), | | Coronary event | no data | | Heart failure | no data | | Diabetes onset | no data | | All cause death | 1.22 [0.96 1.56] | p=1.00 | 0 | 2183 | 1 | MRC I (vs diuretics), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| atenolol vs control | No demonstrated result suggested stroke (fatal and non fatal) by 43% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | 0.78 [0.49 1.22] | p=1.00 | 0 | 884 | 1 | Coope, | | myocardial infarction (fatal and non fatal) | 1.02 [0.63 1.65] | p=1.00 | 0 | 884 | 1 | Coope, | | stroke (fatal and non fatal) | 0.57 [0.33 0.99] | p=0.04 | 0 | 884 | 1 | Coope, | | Coronary event | no data | | Heart failure | 0.68 [0.39 1.17] | p=1.00 | 0 | 884 | 1 | Coope, | | Diabetes onset | no data | | All cause death | 0.97 [0.66 1.40] | p=1.00 | 0 | 884 | 1 | Coope, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| atenolol vs hydrochlorothiazide+amiloride | No demonstrated result suggested cardiovascular events by 38% (not demonstrated) suggested Cardiovascular death by 41% (not demonstrated) suggested myocardial infarction (fatal and non fatal) by 596% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 1.38 [1.06 1.80] | p=0.04 | 0 | 2183 | 1 | MRC old (vs diuretics), | | Cardiovascular death | 1.41 [1.02 1.96] | p=0.04 | 0 | 2183 | 1 | MRC old (vs diuretics), | | myocardial infarction (fatal and non fatal) | 6.96 [4.84 10.02] | p=0.04 | 0 | 5707 | 1 | MRC old (vs diuretics), | | stroke (fatal and non fatal) | 1.22 [0.82 1.82] | p=1.00 | 0 | 2183 | 1 | MRC old (vs diuretics), | | Coronary event | no data | | Heart failure | no data | | Diabetes onset | no data | | All cause death | 1.22 [0.96 1.56] | p=1.00 | 0 | 2183 | 1 | MRC old (vs diuretics), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| atenolol vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 0.92 [0.82 1.04] | p=1.00 | 0 | 18565 | 4 | MRC I (vs placebo),MRC old (vs placebo),Dutch TIA,TEST, | | Cardiovascular death | 0.85 [0.72 1.00] | p=1.00 | 0 | 18565 | 4 | MRC I (vs placebo),MRC old (vs placebo),Dutch TIA,TEST, | | myocardial infarction (fatal and non fatal) | 0.93 [0.79 1.09] | p=1.00 | 0 | 18565 | 4 | MRC I (vs placebo),MRC old (vs placebo),Dutch TIA,TEST, | | stroke (fatal and non fatal) | 0.86 [0.72 1.02] | p=1.00 | 0 | 18565 | 4 | MRC I (vs placebo),MRC old (vs placebo),Dutch TIA,TEST, | | Coronary event | no data | | Heart failure | no data | | Diabetes onset | no data | | All cause death | 0.99 [0.87 1.13] | p=1.00 | 0 | 18565 | 4 | MRC I (vs placebo),MRC old (vs placebo),Dutch TIA,TEST, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Elderly (60 years and more): 2 trials - MRC old (vs placebo) - MRC old (vs diuretics)
| atenolol vs hydrochlorothiazide+amiloride | No demonstrated result suggested cardiovascular events by 38% (not demonstrated) suggested Cardiovascular death by 41% (not demonstrated) suggested myocardial infarction (fatal and non fatal) by 596% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 1.38 [1.06 1.80] | p=0.04 | 0 | 2183 | 1 | MRC old (vs diuretics), | | Cardiovascular death | 1.41 [1.02 1.96] | p=0.04 | 0 | 2183 | 1 | MRC old (vs diuretics), | | myocardial infarction (fatal and non fatal) | 6.96 [4.84 10.02] | p=0.04 | 0 | 5707 | 1 | MRC old (vs diuretics), | | stroke (fatal and non fatal) | 1.22 [0.82 1.82] | p=1.00 | 0 | 2183 | 1 | MRC old (vs diuretics), | | Coronary event | no data | | Heart failure | no data | | Diabetes onset | no data | | All cause death | 1.22 [0.96 1.56] | p=1.00 | 0 | 2183 | 1 | MRC old (vs diuretics), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| atenolol vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 0.98 [0.80 1.21] | p=1.00 | 0 | 3315 | 1 | MRC old (vs placebo), | | Cardiovascular death | 1.06 [0.82 1.37] | p=1.00 | 0 | 3315 | 1 | MRC old (vs placebo), | | myocardial infarction (fatal and non fatal) | 1.01 [0.76 1.34] | p=1.00 | 0 | 3315 | 1 | MRC old (vs placebo), | | stroke (fatal and non fatal) | 0.84 [0.61 1.16] | p=1.00 | 0 | 3315 | 1 | MRC old (vs placebo), | | Coronary event | no data | | Heart failure | no data | | Diabetes onset | no data | | All cause death | 1.06 [0.87 1.30] | p=1.00 | 0 | 3315 | 1 | MRC old (vs placebo), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Post stroke: 2 trials - Dutch TIA - TEST
| atenolol vs placebo | No demonstrated result suggested Cardiovascular death by 41% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 1.01 [0.81 1.27] | p=1.00 | 0 | 2193 | 2 | Dutch TIA,TEST, | | Cardiovascular death | 0.59 [0.43 0.79] | p=0.04 | 0 | 2193 | 2 | Dutch TIA,TEST, | | myocardial infarction (fatal and non fatal) | 0.96 [0.69 1.33] | p=1.00 | 0 | 2193 | 2 | Dutch TIA,TEST, | | stroke (fatal and non fatal) | 0.93 [0.72 1.21] | p=1.00 | 0 | 2193 | 2 | Dutch TIA,TEST, | | Coronary event | no data | | Heart failure | no data | | Diabetes onset | no data | | All cause death | 0.96 [0.73 1.26] | p=1.00 | 0 | 2193 | 2 | Dutch TIA,TEST, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Uncomplicated hypertension: 5 trials - MRC I (vs placebo) - MRC I (vs diuretics) - Coope - MRC old (vs placebo) - MRC old (vs diuretics)
| atenolol vs bendroflumethiazide | No demonstrated result suggested myocardial infarction (fatal and non fatal) by 63% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 1.02 [0.80 1.29] | p=1.00 | 0 | 8700 | 1 | MRC I (vs diuretics), | | Cardiovascular death | 0.92 [0.65 1.29] | p=1.00 | 0 | 8700 | 1 | MRC I (vs diuretics), | | myocardial infarction (fatal and non fatal) | 1.63 [1.13 2.36] | p=0.04 | 0 | 2183 | 1 | MRC I (vs diuretics), | | stroke (fatal and non fatal) | 1.22 [0.82 1.82] | p=1.00 | 0 | 2183 | 1 | MRC I (vs diuretics), | | Coronary event | no data | | Heart failure | no data | | Diabetes onset | no data | | All cause death | 1.22 [0.96 1.56] | p=1.00 | 0 | 2183 | 1 | MRC I (vs diuretics), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| atenolol vs control | No demonstrated result suggested stroke (fatal and non fatal) by 43% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | 0.78 [0.49 1.22] | p=1.00 | 0 | 884 | 1 | Coope, | | myocardial infarction (fatal and non fatal) | 1.02 [0.63 1.65] | p=1.00 | 0 | 884 | 1 | Coope, | | stroke (fatal and non fatal) | 0.57 [0.33 0.99] | p=0.04 | 0 | 884 | 1 | Coope, | | Coronary event | no data | | Heart failure | 0.68 [0.39 1.17] | p=1.00 | 0 | 884 | 1 | Coope, | | Diabetes onset | no data | | All cause death | 0.97 [0.66 1.40] | p=1.00 | 0 | 884 | 1 | Coope, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| atenolol vs hydrochlorothiazide+amiloride | No demonstrated result suggested cardiovascular events by 38% (not demonstrated) suggested Cardiovascular death by 41% (not demonstrated) suggested myocardial infarction (fatal and non fatal) by 596% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 1.38 [1.06 1.80] | p=0.04 | 0 | 2183 | 1 | MRC old (vs diuretics), | | Cardiovascular death | 1.41 [1.02 1.96] | p=0.04 | 0 | 2183 | 1 | MRC old (vs diuretics), | | myocardial infarction (fatal and non fatal) | 6.96 [4.84 10.02] | p=0.04 | 0 | 5707 | 1 | MRC old (vs diuretics), | | stroke (fatal and non fatal) | 1.22 [0.82 1.82] | p=1.00 | 0 | 2183 | 1 | MRC old (vs diuretics), | | Coronary event | no data | | Heart failure | no data | | Diabetes onset | no data | | All cause death | 1.22 [0.96 1.56] | p=1.00 | 0 | 2183 | 1 | MRC old (vs diuretics), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| atenolol vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 0.89 [0.77 1.03] | p=1.00 | 0 | 16372 | 2 | MRC I (vs placebo),MRC old (vs placebo), | | Cardiovascular death | 1.00 [0.82 1.21] | p=1.00 | 0 | 16372 | 2 | MRC I (vs placebo),MRC old (vs placebo), | | myocardial infarction (fatal and non fatal) | 0.92 [0.77 1.10] | p=1.00 | 0 | 16372 | 2 | MRC I (vs placebo),MRC old (vs placebo), | | stroke (fatal and non fatal) | 0.80 [0.63 1.02] | p=1.00 | 0 | 16372 | 2 | MRC I (vs placebo),MRC old (vs placebo), | | Coronary event | no data | | Heart failure | no data | | Diabetes onset | no data | | All cause death | 1.00 [0.86 1.16] | p=1.00 | 0 | 16372 | 2 | MRC I (vs placebo),MRC old (vs placebo), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Very ederly (80 and more): 1 trials - Coope (subgroup )
| atenolol vs control | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 0.44 [0.01 17.09] | p=1.00 | 0 | 7 | 1 | Coope (subgroup ), | | Cardiovascular death | 1.33 [0.02 92.80] | p=1.00 | 0 | 7 | 1 | Coope (subgroup ), | | stroke (fatal and non fatal) | 0.44 [0.01 17.09] | p=1.00 | 0 | 7 | 1 | Coope (subgroup ), | | Coronary event | 1.33 [0.02 92.80] | p=1.00 | 0 | 7 | 1 | Coope (subgroup ), | | Coronary death | 1.33 [0.02 92.80] | p=1.00 | 0 | 7 | 1 | Coope (subgroup ), | | Heart failure | 1.33 [0.02 92.80] | p=1.00 | 0 | 7 | 1 | Coope (subgroup ), | | All cause death | 1.33 [0.02 92.80] | p=1.00 | 0 | 7 | 1 | Coope (subgroup ), | | Fatal stroke | 1.33 [0.02 92.80] | p=1.00 | 0 | 7 | 1 | Coope (subgroup ), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
